Nifedipine Market - Forecast(2021 - 2026)

Report Code: HCR 64488 Report Format: PDF + Excel (Delivery in 48 Hrs)
Nifedipine Market Overview
Nifedipine Market size is forecast to reach $1.37 billion by 2025, growing at a CAGR of 4.07% during the forecast period 2020-2025. Nifedipine is a calcium channel blocker of dihydropyridine type. Increasing usage of nifedipine in preterm labor to improve the baby’s lung function and to treat severely high blood pressure in pregnancy are the major factors driving the growth of the market. Increasing incidence of heart failure and arrhythmias is set to further enhance the overall market demand of nifedipine during the forecast period 2020-2025. 

Report Coverage
The report: “Nifedipine Market Forecast (2020-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Nifedipine Market. 

By Product Type: Nifedipine Controlled Release Tablet and Nifedipine Extended Action Tablet
By Applications: Primary Pulmonary Hypertension, Heart Failure, Raynauds Syndrome, Cephalagra, Bronchial Asthma and Premature Labor
By Geography: North America, Europe, Asia Pacific and Rest of the World (RoW)

Key Takeaways
  • North America dominated the Nifedipine Market in 2019 owing to the increasing number of higher blood pressure patient and increasing number of heart disease. The Nifedipine Market scope for different regions will be provided in the final report.
  • Increasing hypertension and rising number of cirrhosis patients is likely to aid in the market growth of Nifedipine.
  • Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Nifedipine Market report.
  • Stringent government regulations and congestive heart failure is poised to create hurdles for the Nifedipine Market.

Product Type- Segment Analysis
The Nifedipine Controlled Release Tablet segment held the largest share in the Nifedipine Market in 2019 and is estimated to grow at a CAGR of 4.85% during the forecast period 2020-2025 owing to its use to treat angina and high blood pressure. Both the nifedipine immediate-release capsules and extended-release tablets are available as generic drugs. It helps to prevent strokes, heart attacks, and kidney problems. Tachycardia occur as a reaction when patients feel dizzy or faint after taking the first few doses of nifedipine controlled-release tablets. These problems are much less frequent within the sustained-release preparations of nifedipine. Nifedipine controlled-release tablet is used to treat severely high blood pressure in pregnancy and is sold under the brand name Adalat which is used to manage Raynaud's phenomenon and premature labor. Nifedipine Controlled Release Tablet is set to be the highest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025.

Application - Segment Analysis
The Premature Labor held the largest share in the Nifedipine Market in 2019 owing to its usage in preterm labor that allows more time for steroids to improve the baby’s lung function and to treat severely high blood pressure in pregnancy. It is used as a tocolytic which is an agent that delays premature labor and benefits over placebo or no treatment for prolongation of pregnancy. Raynaud’s Syndrome is also treated with nifedipine as it is a calcium channel blocker which is the most potent vasodilator. Nifedipine is a calcium channel blocker that affects the movement of calcium within the cells of the guts and blood vessels. As a result, calcium channel blockers release blood vessels and increase the supply of blood and oxygen to the heart, reducing the chance of heart failure. Premature Labor is set to be the highest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025 owing to its effective use to treat severe hypertension in preterm labor.

Geography - Segment Analysis
North America dominates the nifedipine market with a share of more than 37.7%, followed by the Asia Pacific owing to the increasing number of higher blood pressure patients. Nifedipine is used to treat high blood pressure. It lowers the blood pressure by relaxing the blood vessels so the heart does not have to pump as hard. Increasing incidence of chronic diseases like heart failure and arrhythmias is also increasing the growth of the nifedipine market in this region.
However, Asia Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the increasing incidence of lightheadedness and to control angina which is a kind of chest pain.

Drivers – Nifedipine Market 

  • Increasing hypertension and increasing incidence of chronic diseases
Increasing hypertension and increasing the incidence of chronic disease is increasing the growth of the nifedipine market. Nifedipine is a calcium channel blocking agent that is used to treat high blood pressure. It helps to prevent future heart disease, heart attacks, and strokes to the person who is having high blood pressure. Nifedipine lowers the blood pressure and makes it easier for the heart to pump blood around the body. Hypertension is a significant contributor to cardiovascular events, cardiac death, and kidney disease. Nifedipine is a dihydropyridine calcium channel blocker and short-acting formulation of it is associated with a reflex sympathetic nervous system worsening myocardial ischemia and cerebrovascular ischemia; therefore only longer-acting formulations of nifedipine should be taken for reducing hypertension. Thus, increasing the Nifedipine market during the forecast period 2020-2025.

  • Increasing usage of nifedipine in preterm labor to improve the baby’s lung function and to treat severely high blood pressure in pregnancy
Increasing usage of nifedipine in preterm labor to improve the baby’s lung function and to treat severely high blood pressure in pregnancy is increasing the growth of the nifedipine market owing to its effective use to treat severe hypertension in pregnancy and preterm labor. Nifedipine is a calcium chain blocker that is used to reduce blood pressure and to relax uterine contractions and postpone a preterm birth. The uterus is made up of thousands of muscle cells. When calcium flows to the cell, the muscle relaxes and calcium chain blocker prevents calcium to move into the muscle cells of the uterus making it less able to contract. Nifedipine can reduce the number of frequency of contractions but its effect and how long it lasts that varies from one woman to another. Thus, increasing the nifedipine market during the forecast period 2020-2025.

Challenges – Nifedipine Market  

  • Stringent government regulations and congestive heart failure 
Some of the factors which can impede the growth of the Nifedipine markets are stringent government regulations and side effects like hypotension and congestive heart failure.

Nifedipine Industry Outlook
Product launches, mergers and acquisitions, joint ventures, and R&D activities are key strategies adopted by players in the nifedipine market. In 2019, Nifedipine Market share is consolidated by the top ten players present in the market. Nifedipine, the top 10 companies are  Abbott Laboratory, AstraZeneca Plc, Boehringer Ingelheim Gmbh, F. Hoffmann-La Roche Ag, GlaxoSmithKline Plc, Merck Co, Inc, Novartis Ag, Pifizer Inc, Teva Pharmaceutical Industry Ltd, and Vectura Group Plc among others

Acquisitions/Product Launches
  • In June 2017, Abbott Laboratory acquired St. Jude Medical.
  • In January 2019, Glaxosmithkline Plc acquired Tesaro.
 
1. Nifedipine Market  - Overview
    1.1 Definitions and Scope
2. Nifedipine Market  - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Product
    2.3 Key trends by Application
    2.4 Key trends by Geography
3. Nifedipine Market  – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Nifedipine Market  - Startup Companies Scenario (Premium)
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Nifedipine Market  – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Nifedipine Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Nifedipine Market  – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Nifedipine Market  – By Product (Market Size –$Million/$Billion)
    8.1 Nifedipine Controlled Release Tablet
    8.2 Nifedipine Extended Action Tablet
9. Nifedipine Market   – By Application (Market Size –$Million/$Billion)
    9.1 Primary Pulmonary Hypertension
    9.2 Heart Failure
    9.3 Raynauds Syndrome
    9.4 Cephalagra
    9.5 Bronchial Asthma
    9.6 Premature Labor
10. Nifedipine Market  - By Geography 
    10.1 North America
        10.1.1 U.S.
        10.1.2 Mexico
        10.1.3 Canada
    10.2 Europe
        10.2.1 U.K.
        10.2.2 France
        10.2.3 Germany
        10.2.4 Italy
        10.2.5 Spain
        10.2.6 Rest of Europe
    10.3 Asia Pacific
        10.3.1 China
        10.3.2 India
        10.3.3 Japan
        10.3.4 South Korea
        10.3.5 Australia
        10.3.6 New Zealand
        10.3.7 Rest of APAC
    10.4 Rest of the World
        10.4.1 Middle East
        10.4.2 Africa
        10.4.3 South America
11. Nifedipine Market  - Entropy
12. Nifedipine Market  – Industry/Segment Competition Landscape (Premium) 
    12.1 Market Share Analysis
        12.1.1 Global Market Share – Key Companies
        12.1.2 Market Share by Region – Key companies
        12.1.3 Market Share by Countries – Key Companies
        12.1.4 Best Practices for Companies
13. Nifedipine Market  – Key Company List by Country Premium (Premium)
14. Nifedipine Market  Company Analysis
    14.1 Company 1
    14.2 Company 2
    14.3 Company 3
    14.4 Company 4
    14.5 Company 5
    14.6 Company 6
    14.7 Company 7
    14.8 Company 8
    14.9 Company 9
    14.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global Nifedipine , By Product Market 2019-2024 ($M)
1.1 Nifedipine Controlled Release Tablet Market 2019-2024 ($M) - Global Industry Research
1.2 Nifedipine Extended Action Tablet Market 2019-2024 ($M) - Global Industry Research
2.Global Nifedipine , By Product Market 2019-2024 (Volume/Units)
2.1 Nifedipine Controlled Release Tablet Market 2019-2024 (Volume/Units) - Global Industry Research
2.2 Nifedipine Extended Action Tablet Market 2019-2024 (Volume/Units) - Global Industry Research
3.North America Nifedipine , By Product Market 2019-2024 ($M)
3.1 Nifedipine Controlled Release Tablet Market 2019-2024 ($M) - Regional Industry Research
3.2 Nifedipine Extended Action Tablet Market 2019-2024 ($M) - Regional Industry Research
4.South America Nifedipine , By Product Market 2019-2024 ($M)
4.1 Nifedipine Controlled Release Tablet Market 2019-2024 ($M) - Regional Industry Research
4.2 Nifedipine Extended Action Tablet Market 2019-2024 ($M) - Regional Industry Research
5.Europe Nifedipine , By Product Market 2019-2024 ($M)
5.1 Nifedipine Controlled Release Tablet Market 2019-2024 ($M) - Regional Industry Research
5.2 Nifedipine Extended Action Tablet Market 2019-2024 ($M) - Regional Industry Research
6.APAC Nifedipine , By Product Market 2019-2024 ($M)
6.1 Nifedipine Controlled Release Tablet Market 2019-2024 ($M) - Regional Industry Research
6.2 Nifedipine Extended Action Tablet Market 2019-2024 ($M) - Regional Industry Research
7.MENA Nifedipine , By Product Market 2019-2024 ($M)
7.1 Nifedipine Controlled Release Tablet Market 2019-2024 ($M) - Regional Industry Research
7.2 Nifedipine Extended Action Tablet Market 2019-2024 ($M) - Regional Industry Research

LIST OF FIGURES

1.US Nifedipine Market Revenue, 2019-2024 ($M)
2.Canada Nifedipine Market Revenue, 2019-2024 ($M)
3.Mexico Nifedipine Market Revenue, 2019-2024 ($M)
4.Brazil Nifedipine Market Revenue, 2019-2024 ($M)
5.Argentina Nifedipine Market Revenue, 2019-2024 ($M)
6.Peru Nifedipine Market Revenue, 2019-2024 ($M)
7.Colombia Nifedipine Market Revenue, 2019-2024 ($M)
8.Chile Nifedipine Market Revenue, 2019-2024 ($M)
9.Rest of South America Nifedipine Market Revenue, 2019-2024 ($M)
10.UK Nifedipine Market Revenue, 2019-2024 ($M)
11.Germany Nifedipine Market Revenue, 2019-2024 ($M)
12.France Nifedipine Market Revenue, 2019-2024 ($M)
13.Italy Nifedipine Market Revenue, 2019-2024 ($M)
14.Spain Nifedipine Market Revenue, 2019-2024 ($M)
15.Rest of Europe Nifedipine Market Revenue, 2019-2024 ($M)
16.China Nifedipine Market Revenue, 2019-2024 ($M)
17.India Nifedipine Market Revenue, 2019-2024 ($M)
18.Japan Nifedipine Market Revenue, 2019-2024 ($M)
19.South Korea Nifedipine Market Revenue, 2019-2024 ($M)
20.South Africa Nifedipine Market Revenue, 2019-2024 ($M)
21.North America Nifedipine By Application
22.South America Nifedipine By Application
23.Europe Nifedipine By Application
24.APAC Nifedipine By Application
25.MENA Nifedipine By Application
26.Glaxosmithkline Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Novartis Ag, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Merck Co , Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Abbott Laboratory, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Boehringer Ingelheim Gmbh, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Astrazeneca Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.F. Hoffmann-La Roche Ag, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Teva Pharmaceutical Industry Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Vectura Group Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Pifizer Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)